The study is a 24-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mg in subjects with moderate to severe postmenopausal VMS, defined as follows:~Moderate VMS: Sensation of heat with sweating, able to continue activity~Severe VMS: Sensation of heat with sweating, causing cessation of activity~The study is comprised of a screening period, a run-in period, a baseline visit, and a double-blind treatment period.
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause